The quarter came in below the published financial bar. Collaboration revenue was $9.0 million versus a published consensus of roughly $15.45 million, while the $43.4 million net loss was directionally worse than the roughly $0.34-per-share loss expected; the filing excerpt does not provide weighted-average shares needed to calculate exact reported EPS. (Financial Results; Income Statement)
| Metric | Q2 2026 | Comparison / expectation |
|---|---|---|
| Collaboration revenue | $9.0 million | $23.2 million in Q2 2025; published consensus ~ $15.45 million (Financial Results) |
| R&D expense | $48.0 million | $30.7 million in Q2 2025 (Income Statement) |
| G&A expense | $10.1 million | $8.1 million in Q2 2025 (Income Statement) |
| Net loss | $43.4 million | $12.3 million loss in Q2 2025 (Income Statement) |
| Cash, cash equivalents, restricted cash and marketable securities | $626.0 million | $671.2 million at March 31, 2026; runway stated into 2029 (Cash Position and Financial Guidance) |
| Shares outstanding | 85.2 million | 65.5 million at December 31, 2025 (Balance Sheet) |
The revenue miss reflects the lumpy nature of partner payments, but it still weakens the quarter materially. Collaboration revenue fell 61% year over year, and first-half revenue was only $13.2 million versus $108.1 million in the prior-year period because milestone-related revenue was much lower. At the same time, R&D spending rose 56% as Monte Rosa accelerated MRT-8102 and other programs, pushing the company further into operating losses. (Income Statement)
The clinical update preserves the main investment thesis rather than creating a new one. GFORCE-1 enrollment and dosing are complete with an H2 2026 readout still expected, while GFORCE-2, GEMINI-1 and GALAXY-1 remain planned for the previously stated windows. Novartis also activated the MRT-6160 Phase 2 Sjögren’s study, and Monte Rosa activated the small, up-to-25-patient MODeFIRe-1 Phase 2 prostate-cancer study. These are tangible execution milestones, but the filing provides no new efficacy data beyond the previously disclosed 85% median CRP reduction. (Recent Highlights; Anticipated Upcoming Milestones)
The balance sheet is strong enough to fund the next catalyst cycle, but the capital structure is more diluted. The company reports $626.0 million of liquidity and says it can operate into 2029, which reduces near-term financing risk. However, shares outstanding rose from 65.5 million to 85.2 million between December 31, 2025 and June 30, 2026—about a 30% increase—so the stronger cash position came alongside materially more equity dilution. (Balance Sheet; Cash Position and Financial Guidance)
Net read: operational progress was broadly intact, but it did not offset the financial miss. The filing keeps the major catalysts on schedule and adds partner-funded Phase 2 activity through Novartis, yet it offers no fresh clinical proof while reporting sharply lower collaboration revenue, higher spending and a larger-than-expected loss. That makes the quarter worse than the market’s financial expectation, though the cash runway limits the damage to the near-term development plan.
Read the original 8-K on SEC EDGAR ↗